应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AGIO Agios Pharmaceuticals, Inc.
休市中 01-02 16:00:00 EST
27.18
-0.04
-0.15%
盘后
27.10
-0.08
-0.29%
19:40 EST
最高
27.25
最低
26.56
成交量
93.52万
今开
27.25
昨收
27.22
日振幅
2.53%
总市值
15.85亿
流通市值
13.96亿
总股本
5,831万
成交额
2,523万
换手率
1.82%
流通股本
5,135万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
高盛上调Agios(AGIO.US)目标价至28美元,看好地中海贫血新药Aqvesme上市前景
智通财经 · 2025-12-26
高盛上调Agios(AGIO.US)目标价至28美元,看好地中海贫血新药Aqvesme上市前景
血液疾病药物获美国FDA批准扩大使用范围,Agios Pharmaceuticals股价飙涨近20%
智通财经 · 2025-12-25
血液疾病药物获美国FDA批准扩大使用范围,Agios Pharmaceuticals股价飙涨近20%
Agios Pharmaceuticals高管表示Aqvesme的年度费用约为每位患者425,000美元 - 财报电话会议
美股速递 · 2025-12-24
Agios Pharmaceuticals高管表示Aqvesme的年度费用约为每位患者425,000美元 - 财报电话会议
Agios Pharmaceuticals, Inc. 股份在盘前上涨 9.8%,因美国 FDA 批准其治疗血液疾病成人贫血的药物
美股速递 · 2025-12-24
Agios Pharmaceuticals, Inc. 股份在盘前上涨 9.8%,因美国 FDA 批准其治疗血液疾病成人贫血的药物
美国FDA批准Agios的Aqvesme™(Mitapivat)用于治疗成人α或β地中海贫血引起的贫血
美股速递 · 2025-12-24
美国FDA批准Agios的Aqvesme™(Mitapivat)用于治疗成人α或β地中海贫血引起的贫血
Agios Pharmaceuticals, Inc.盘中异动 临近午盘大幅拉升5.08%报27.84美元
市场透视 · 2025-11-26
Agios Pharmaceuticals, Inc.盘中异动 临近午盘大幅拉升5.08%报27.84美元
Agios Pharmaceuticals, Inc.股价重挫50.21% 市值跌6.63亿美元
市场透视 · 2025-11-19
Agios Pharmaceuticals, Inc.股价重挫50.21% 市值跌6.63亿美元
Agios公司公布镰状细胞贫血症研究结果喜忧参半,引发对该药物未来前景担忧
老虎资讯综合 · 2025-11-19
Agios公司公布镰状细胞贫血症研究结果喜忧参半,引发对该药物未来前景担忧
Agios Pharmaceuticals股价盘前下跌35.1%,因晚期镰状细胞药物试验未能实现主要目标之一
美股速递 · 2025-11-19
Agios Pharmaceuticals股价盘前下跌35.1%,因晚期镰状细胞药物试验未能实现主要目标之一
Agios:试验显示Mitapivat有利趋势,但在年度Scpcs发生率的主要终点上未达到统计显著性
美股速递 · 2025-11-19
Agios:试验显示Mitapivat有利趋势,但在年度Scpcs发生率的主要终点上未达到统计显著性
Agios Pharmaceuticals, Inc.盘中异动 早盘股价大跌13.26%
市场透视 · 2025-09-04
Agios Pharmaceuticals, Inc.盘中异动 早盘股价大跌13.26%
Agios Pharmaceuticals, Inc.2025财年第二财季实现净利润-1.12亿美元,同比减少16.52%
市场透视 · 2025-08-09
Agios Pharmaceuticals, Inc.2025财年第二财季实现净利润-1.12亿美元,同比减少16.52%
Agios Pharmaceuticals, Inc.股价重挫12.83% 市值跌2.27亿美元
市场透视 · 2025-08-04
Agios Pharmaceuticals, Inc.股价重挫12.83% 市值跌2.27亿美元
Agios Pharmaceuticals, Inc.盘中异动 大幅跳水5.00%报35.36美元
市场透视 · 2025-08-02
Agios Pharmaceuticals, Inc.盘中异动 大幅跳水5.00%报35.36美元
Agios Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.05%
市场透视 · 2025-07-29
Agios Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.05%
Agios Pharmaceuticals, Inc.盘中异动 快速拉升5.15%报38.15美元
市场透视 · 2025-07-09
Agios Pharmaceuticals, Inc.盘中异动 快速拉升5.15%报38.15美元
Agios Pharmaceuticals, Inc.盘中异动 快速下挫5.41%
市场透视 · 2025-03-03
Agios Pharmaceuticals, Inc.盘中异动 快速下挫5.41%
Agios Pharmaceuticals, Inc.2024财年实现净利润6.74亿美元,同比增加291.48%
市场透视 · 2025-02-17
Agios Pharmaceuticals, Inc.2024财年实现净利润6.74亿美元,同比增加291.48%
Agios制药公司第四季度销售额1070万美元,高于预期的933万美元,净亏损9650万美元同比相比9590万美元,现金余额15亿美元
财报速递 · 2025-02-13
Agios制药公司第四季度销售额1070万美元,高于预期的933万美元,净亏损9650万美元同比相比9590万美元,现金余额15亿美元
暂无数据
公司概况
公司名称:
Agios Pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Agios Pharmaceuticals, Inc.于2007年8月7日在特拉华州注册成立。该公司是一家生物制药公司,致力于通过细胞代谢领域的领导地位改变患者的生活,目标是为罕见病创造差异化药物,重点是经典血液学。
发行价格:
--
{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals, Inc.","latestPrice":27.18,"timestamp":1767387600000,"preClose":27.22,"halted":0,"volume":935215,"hourTrading":{"tag":"盘后","latestPrice":27.1,"preClose":27.18,"latestTime":"19:40 EST","volume":87412,"amount":2379315.86,"timestamp":1767400800237},"delay":0,"floatShares":51348506,"shares":58313812,"eps":-6.962485,"marketStatus":"休市中","change":-0.04,"latestTime":"01-02 16:00:00 EST","open":27.25,"high":27.25,"low":26.56,"amount":25232836.714205,"amplitude":0.025349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.962485,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767603600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":27.22,"preHourTrading":{"tag":"盘前","latestPrice":27.16,"preClose":27.22,"latestTime":"09:28 EST","volume":10,"amount":273.34,"timestamp":1767364087097},"postHourTrading":{"tag":"盘后","latestPrice":27.1,"preClose":27.18,"latestTime":"19:40 EST","volume":87412,"amount":2379315.86,"timestamp":1767400800237},"volumeRatio":0.43481095823975346,"impliedVol":0.61,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/AGIO/tweets","defaultTab":"tweets","newsList":[{"id":"2594955102","title":"高盛上调Agios(AGIO.US)目标价至28美元,看好地中海贫血新药Aqvesme上市前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2594955102","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594955102?lang=zh_cn&edition=full","pubTime":"2025-12-26 19:19","pubTimestamp":1766747977,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,高盛把Agios Pharmaceuticals的12个月目标价从25美元上调至28美元,对应潜在涨幅约14%,维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme获FDA批准后的市场前景与风险评估。ENERGIZE-T方面,Aqvesme组10%的病人在48周内摆脱输血,安慰剂组只有1%,输血负荷下降幅度同样显著。综合来看,高盛认为Agios短期靠Aqvesme美国上市兑现第一波价值,中期看处方-收入错配何时收敛,长期则取决于镰状细胞病适应症能否再下一城。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIO"],"gpt_icon":0},{"id":"2594283351","title":"血液疾病药物获美国FDA批准扩大使用范围,Agios Pharmaceuticals股价飙涨近20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594283351","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594283351?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:35","pubTimestamp":1766622949,"startTime":"0","endTime":"0","summary":"12月25日,$美国食品$药品监督管理局批准了Agios Pharmaceuticals药物用于治疗某种血液疾病的扩大适应症,该股股价周三大幅上涨18.63%。地中海贫血是一种遗传性血液疾病,影响人体产生血红蛋白和健康红细胞的能力。在实施一项必需的安全计划后,Aqvesme预计将于下个月晚些时候上市。药品标签还将建议肝硬化患者不要使用。该药物已于2022年获得FDA批准,用于治疗成人丙酮酸激酶缺乏症所致的红细胞计数低下。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385732.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"血液疾病药物获美国FDA批准扩大使用范围,Agios Pharmaceuticals股价飙涨近20%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"1142894347","title":"Agios Pharmaceuticals高管表示Aqvesme的年度费用约为每位患者425,000美元 - 财报电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1142894347","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142894347?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:28","pubTimestamp":1766582890,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals高管表示Aqvesme的引入费用大约为每位患者每年425,000美元 - 财报电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"1177135129","title":"Agios Pharmaceuticals, Inc. 股份在盘前上涨 9.8%,因美国 FDA 批准其治疗血液疾病成人贫血的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1177135129","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177135129?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:25","pubTimestamp":1766579112,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. 股份在盘前上涨 9.8%,因美国 FDA 批准其治疗血液疾病成人贫血的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"1193620418","title":"美国FDA批准Agios的Aqvesme™(Mitapivat)用于治疗成人α或β地中海贫血引起的贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=1193620418","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193620418?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:45","pubTimestamp":1766537109,"startTime":"0","endTime":"0","summary":"美国FDA批准Agios的Aqvesme™(Mitapivat)用于治疗成人α或β地中海贫血引起的贫血","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2586231238","title":"Agios Pharmaceuticals, Inc.盘中异动 临近午盘大幅拉升5.08%报27.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586231238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586231238?lang=zh_cn&edition=full","pubTime":"2025-11-26 00:47","pubTimestamp":1764089237,"startTime":"0","endTime":"0","summary":"北京时间2025年11月26日00时47分,Agios Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.08%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.17%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126004717a7110a28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126004717a7110a28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2584180017","title":"Agios Pharmaceuticals, Inc.股价重挫50.21% 市值跌6.63亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584180017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584180017?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:31","pubTimestamp":1763562687,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日22时31分,Agios Pharmaceuticals, Inc.股票出现波动,股价急速下跌50.21%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.02%。其相关个股中,Kazia Therapeutics Limited、Biovie Inc C/Wts 08/08/2030、Fulcrum Therapeutics, Inc.涨幅较大,Kazia Therapeutics Limited、Clearmind Medicine Inc.、Can Fite Biopharma Ltd较为活跃,换手率分别为793.20%、68.35%、23.45%,振幅较大的相关个股有Bioatla, Inc.、Fulcrum Therapeutics, Inc.、冠科美博,振幅分别为9.84%、9.15%、8.04%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119223127a4ad1185&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119223127a4ad1185&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"1125155038","title":"Agios公司公布镰状细胞贫血症研究结果喜忧参半,引发对该药物未来前景担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1125155038","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125155038?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:17","pubTimestamp":1763558255,"startTime":"0","endTime":"0","summary":"11月19日,Agios Pharmaceuticals盘前跌近59%!周三公布了一项针对镰状细胞病的 3 期研究结果喜忧参半,这可能会降低其药物获得美国批准的希望。 在为期一年的研究中,接受 Agios 药物 Pyrukynd 治疗的患者中有 41% 的血红蛋白水平得到改善,而接受安慰剂治疗的参与者中只有 3% 的人达到了这一改善——这一结果具有统计学意义,并实现了两个主要研究目标之一。 ","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Agios公司公布镰状细胞贫血症研究结果喜忧参半,引发对该药物未来前景担忧","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"1140122793","title":"Agios Pharmaceuticals股价盘前下跌35.1%,因晚期镰状细胞药物试验未能实现主要目标之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1140122793","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140122793?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:22","pubTimestamp":1763554935,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals股价盘前下跌35.1%,因晚期镰状细胞药物试验未能实现主要目标之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5d18614bb841112089a87d6203a0bc12","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"1168351762","title":"Agios:试验显示Mitapivat有利趋势,但在年度Scpcs发生率的主要终点上未达到统计显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1168351762","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168351762?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:02","pubTimestamp":1763553752,"startTime":"0","endTime":"0","summary":"Agios:试验显示Mitapivat有利趋势,但在年度Scpcs发生率的主要终点上未达到统计显著性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2565587401","title":"Agios Pharmaceuticals, Inc.盘中异动 早盘股价大跌13.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565587401","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565587401?lang=zh_cn&edition=full","pubTime":"2025-09-04 21:31","pubTimestamp":1756992662,"startTime":"0","endTime":"0","summary":"北京时间2025年09月04日21时31分,Agios Pharmaceuticals, Inc.股票出现波动,股价急速跳水13.26%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.07%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904213102a4b40dd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904213102a4b40dd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2558057689","title":"Agios Pharmaceuticals, Inc.2025财年第二财季实现净利润-1.12亿美元,同比减少16.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558057689","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558057689?lang=zh_cn&edition=full","pubTime":"2025-08-09 00:00","pubTimestamp":1754668842,"startTime":"0","endTime":"0","summary":"8月9日,Agios Pharmaceuticals, Inc.公布财报,公告显示公司2025财年第二财季净利润为-1.12亿美元,同比减少16.52%;其中营业收入为12.46百万美元,同比增加44.55%,每股基本收益为-1.93美元。机构评级:截至2025年8月9日,当前有7家机构对Agios Pharmaceuticals, Inc.目标价做出预测,其中目标均价为50.14美元,其中最低目标价为37.00美元,最高目标价为65.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809000105a47d91a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809000105a47d91a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO"],"gpt_icon":0},{"id":"2556909382","title":"Agios Pharmaceuticals, Inc.股价重挫12.83% 市值跌2.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556909382","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556909382?lang=zh_cn&edition=full","pubTime":"2025-08-04 21:32","pubTimestamp":1754314341,"startTime":"0","endTime":"0","summary":"北京时间2025年08月04日21时32分,Agios Pharmaceuticals, Inc.股票出现异动,股价大幅跳水12.83%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.60%。其相关个股中,Psyence Biomedical Ltd.、Soligenix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Psyence Biomedical Ltd.、Soligenix, Inc.、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为2217.65%、801.47%、388.27%,振幅较大的相关个股有Psyence Biomedical Ltd.、凯信远达、Bioxcel Therapeutics, Inc.,振幅分别为21.40%、15.35%、13.50%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804213222a4748fc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804213222a4748fc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2556429810","title":"Agios Pharmaceuticals, Inc.盘中异动 大幅跳水5.00%报35.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556429810","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556429810?lang=zh_cn&edition=full","pubTime":"2025-08-02 00:50","pubTimestamp":1754067038,"startTime":"0","endTime":"0","summary":"北京时间2025年08月02日00时50分,Agios Pharmaceuticals, Inc.股票出现异动,股价快速下挫5.00%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.26%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802005038972d52f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802005038972d52f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2555570675","title":"Agios Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555570675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555570675?lang=zh_cn&edition=full","pubTime":"2025-07-29 03:28","pubTimestamp":1753730906,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日03时28分,Agios Pharmaceuticals, Inc.股票出现异动,股价快速下挫5.05%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.39%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072903282694bfe5d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072903282694bfe5d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2550659361","title":"Agios Pharmaceuticals, Inc.盘中异动 快速拉升5.15%报38.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659361","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550659361?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:52","pubTimestamp":1752072748,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时52分,Agios Pharmaceuticals, Inc.股票出现波动,股价急速拉升5.15%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.15%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709225229953c4723&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709225229953c4723&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2516630865","title":"Agios Pharmaceuticals, Inc.盘中异动 快速下挫5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630865?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:45","pubTimestamp":1741013140,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时45分,Agios Pharmaceuticals, Inc.股票出现波动,股价急速下跌5.41%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.24%。Agios Pharmaceuticals, Inc.公司简介:Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司,旨在为罕见疾病开发差异化药物,其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224541abe63813&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224541abe63813&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2512207953","title":"Agios Pharmaceuticals, Inc.2024财年实现净利润6.74亿美元,同比增加291.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512207953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512207953?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:01","pubTimestamp":1739721663,"startTime":"0","endTime":"0","summary":"2月17日,Agios Pharmaceuticals, Inc.公布财报,公告显示公司2024财年净利润为6.74亿美元,同比增加291.48%;其中营业收入为36.50百万美元,同比增加36.09%,每股基本收益为11.86美元。机构评级:截至2025年2月17日,当前有6家机构对Agios Pharmaceuticals, Inc.目标价做出预测,其中目标均价为56.67美元,其中最低目标价为45.00美元,最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000114a2481c17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000114a2481c17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO"],"gpt_icon":0},{"id":"1158994754","title":"Agios制药公司第四季度销售额1070万美元,高于预期的933万美元,净亏损9650万美元同比相比9590万美元,现金余额15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158994754","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158994754?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:42","pubTimestamp":1739446968,"startTime":"0","endTime":"0","summary":"Agios制药公司发布了第四季度财报,报告显示销售额为1070万美元,高于预期的933万美元。公司的净亏损为9650万美元,而去年同期为9590万美元。此外,公司目前的现金余额为15亿美元。以上内容来自Benzinga Earnings专栏,原文如下:N","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.3289},{"period":"6month","weight":-0.2465},{"period":"1year","weight":-0.1464},{"period":"ytd","weight":-0.0015}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agios Pharmaceuticals, Inc.于2007年8月7日在特拉华州注册成立。该公司是一家生物制药公司,致力于通过细胞代谢领域的领导地位改变患者的生活,目标是为罕见病创造差异化药物,重点是经典血液学。","yearOnYearQuotes":[{"month":1,"riseRate":0.769231,"avgChangeRate":0.039658},{"month":2,"riseRate":0.666667,"avgChangeRate":0.057106},{"month":3,"riseRate":0.5,"avgChangeRate":-0.011652},{"month":4,"riseRate":0.583333,"avgChangeRate":0.006741},{"month":5,"riseRate":0.583333,"avgChangeRate":0.052252},{"month":6,"riseRate":0.666667,"avgChangeRate":0.045835},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.012275},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals, Inc.","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Agios Pharmaceuticals, Inc.(AGIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Agios Pharmaceuticals, Inc.,AGIO,Agios Pharmaceuticals, Inc.股票,Agios Pharmaceuticals, Inc.股票老虎,Agios Pharmaceuticals, Inc.股票老虎国际,Agios Pharmaceuticals, Inc.行情,Agios Pharmaceuticals, Inc.股票行情,Agios Pharmaceuticals, Inc.股价,Agios Pharmaceuticals, Inc.股市,Agios Pharmaceuticals, Inc.股票价格,Agios Pharmaceuticals, Inc.股票交易,Agios Pharmaceuticals, Inc.股票购买,Agios Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Agios Pharmaceuticals, Inc.(AGIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}